ARS Pharma will present a late-breaking oral presentation and six poster presentations showcasing the real-world impact of neffy (epinephrine nasal spray). The oral presentation revealed that 9 out of 10 patients with anaphylaxis were effectively treated with a single dose of neffy. Case reports detailed successful use of neffy during oral food challenges or allergy immunotherapy. The presentations will be featured at the American College of Allergy, Asthma & Immunology meeting in Orlando, FL from November 6-10, 2025, highlighting the effectiveness of intranasal epinephrine in treating severe allergies, providing confidence in needle-free administration. Attendees are encouraged to visit the ARS Pharma booth and presentations to learn more about neffy.

Read more at GlobeNewswire: ARS Pharma to Present Real-World Data on Intranasal